{
    "clinical_study": {
        "@rank": "151198", 
        "acronym": "PK", 
        "arm_group": [
            {
                "arm_group_label": "Group 1: BMS-914143 (eGFR \u2265 80 mL/min/1.73 m2)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-914143 (Peginterferon Lambda-1a) single 180 \u00b5g Solution, Subcutaneous injection for subjects with normal renal function with eGFR \u2265 80 mL/min/1.73 m2"
            }, 
            {
                "arm_group_label": "Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-914143 (Peginterferon Lambda-1a) single 180 \u00b5g Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2"
            }, 
            {
                "arm_group_label": "Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-914143 (Peginterferon Lambda-1a) single 180 \u00b5g Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2"
            }, 
            {
                "arm_group_label": "Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-914143 (Peginterferon Lambda-1a) single 180 \u00b5g Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2"
            }, 
            {
                "arm_group_label": "Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-914143 (Peginterferon Lambda-1a) single 180 \u00b5g Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR < 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of renal impairment on pharmacokinetics\n      (PK) of BMS-914143."
        }, 
        "brief_title": "Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Hepatitis B Virus Infection", 
            "Chronic Hepatitis C Virus Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Encephalitis, Herpes Simplex", 
                "Virus Diseases", 
                "Hepatitis B, Chronic", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary purpose: Protocol designed to evaluate the effect of renal impairment on\n      pharmacokinetics of BMS-914143"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Normal renal function or mild, moderate, severe or end-stage renal dysfunction\n\n        Exclusion Criteria:\n\n          -  History of uncontrolled or unstable cardiovascular, respiratory, gastrointestinal,\n             hepatic, endocrine, hematopoietic, psychiatric or neurological conditions within 6\n             months of Lambda administration\n\n          -  History of chronic liver disease including cirrhosis, hepatitis B virus (HBV),\n             hepatitis C virus (HCV), primary biliary cirrhosis, etc\n\n          -  History of central nervous system or neuro-psychiatric disease. Subjects with severe\n             depression and/or other uncontrolled psychiatric conditions should not be enrolled in\n             this study\n\n          -  History of of suicide attempt within the 5 years preceding BMS-914143 administration\n\n          -  Inability to tolerate subcutaneous injections\n\n          -  Donation of >400 mL of blood within 8 weeks or plasma within 4 weeks of planned\n             dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708889", 
            "org_study_id": "AI452-019"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1: BMS-914143 (eGFR \u2265 80 mL/min/1.73 m2)", 
                "Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)", 
                "Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)", 
                "Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)", 
                "Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)"
            ], 
            "intervention_name": "BMS-914143 (Peginterferon Lambda-1a)", 
            "intervention_type": "Biological", 
            "other_name": "Lambda"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 4, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014-3616"
                    }, 
                    "name": "Clinical Pharmacology Of Miami Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "New Orleans Center For Clinical Research - Knoxville"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the serum concentration-time curve from time 0 extrapolated to infinity [AUC(INF)] of a single 180-\u03bcg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to Day 29"
            }, 
            {
                "measure": "Area under the serum concentration-time curve from time 0 to the time of last quantifiable concentration [AUC(0-T)] of a single 180-\u03bcg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to Day 29"
            }, 
            {
                "measure": "Maximum observed serum concentration (Cmax) of a single 180-\u03bcg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to Day 29"
            }, 
            {
                "measure": "Apparent volume of distribution (Vz/F) of a single 180-\u03bcg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to Day 29"
            }, 
            {
                "measure": "Total body clearance (CLT/F) of a single 180-\u03bcg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to Day 29"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to maximum observed serum concentration (Tmax) using serum levels of Lambda", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to Day 29"
            }, 
            {
                "measure": "Half life (T-HALF) using serum levels of Lambda", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to Day 29"
            }, 
            {
                "measure": "Immunogenicity assessed by serum levels of anti-Lambda antibodies", 
                "safety_issue": "No", 
                "time_frame": "5 time points up to Day 43"
            }, 
            {
                "measure": "Safety assessed by Vital signs measurements, electrocardiograms (ECGs), clinical laboratory tests, marked laboratory abnormalities, physical measurements, and adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 43"
            }, 
            {
                "measure": "Serious adverse events (SAEs) Safety assessed by Vital signs measurements, electrocardiograms (ECGs), clinical laboratory tests, marked laboratory abnormalities, physical measurements, and adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to Day 73"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}